An outpatient, randomised, double-blind, placebo controlled, parallel group exploratory study to evaluate safety, tolerability and efficacy of GW679769 [casopitant] in patients with fibromyalgia syndrome comorbid with depression.

Trial Profile

An outpatient, randomised, double-blind, placebo controlled, parallel group exploratory study to evaluate safety, tolerability and efficacy of GW679769 [casopitant] in patients with fibromyalgia syndrome comorbid with depression.

Completed
Phase of Trial: Phase II

Latest Information Update: 24 Apr 2015

At a glance

  • Drugs Casopitant (Primary)
  • Indications Depression; Fibromyalgia
  • Focus Therapeutic Use
  • Sponsors GlaxoSmithKline
  • Most Recent Events

    • 14 Oct 2008 Trial phase changed from I/II to II as reported by ClinicalTrials.gov.
    • 15 Sep 2006 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top